Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
May 09 2022 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system disorders, today announced that it will
host a conference call and live webcast at 8:30 a.m. ET on Monday,
May 16, 2022, to report its first quarter 2022 financial results
and discuss recent business highlights.
To access the live conference call, please dial
833-528-0605 (domestic) or 830-221-9711 (international) and refer
to conference ID 6960234. A live audio webcast of the event will be
available on the Investors & News section of Passage Bio’s
website at investors.passagebio.com. The archived webcast will be
available on Passage Bio's website approximately two hours after
the completion of the event and for 30 days following the call.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage
genetic medicines company on a mission to provide life-transforming
therapies for patients with CNS diseases with limited or no
approved treatment options. Our portfolio spans pediatric and adult
CNS indications, and we are currently advancing three clinical
programs in GM1 gangliosidosis, Krabbe disease and frontotemporal
dementia with several additional programs in preclinical
development. Based in Philadelphia, PA, our company has established
a strategic collaboration and licensing agreement with the renowned
University of Pennsylvania’s Gene Therapy Program to conduct our
discovery and IND-enabling preclinical work. Through this
collaboration, we have enhanced access to a broad portfolio of gene
therapy candidates and future gene therapy innovations that we then
pair with our deep clinical, regulatory, manufacturing and
commercial expertise to rapidly advance our robust pipeline of
optimized gene therapies. As we work with speed and tenacity, we
are always mindful of patients who may be able to benefit from our
therapies. More information is available at www.passagebio.com.
For further information, please
contact:
Passage Bio Investors:
Stuart HendersonPassage
Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:
Mike BeyerSam Brown Inc. Healthcare
Communications312-961-2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2023 to Sep 2024